Associated British Foods acquires Elementis plc for EUR 34,300,000 (2026)

Deal facts

Buyer: Associated British Foods
Target: Elementis plc
Deal value: EUR 34,300,000
Announced: 2 June 2026
Status: Completed
Sector: Healthcare
Country: United Kingdom
Consideration: cash

Sources

What we know

Associated British Foods has agreed to acquire Elementis plc in a strategic acquisition valued at 34.3 million EUR. The transaction was executed entirely in cash and covers the enterprise value of the target business. Both the buyer and the target are headquartered in the United Kingdom, operating within the healthcare sector. The deal was announced and completed on the same day, 2 June 2026, indicating a swift and decisive transaction process between the two parties.

The management team of the acquired entity will now operate under the ownership of Associated British Foods. This acquisition represents a significant consolidation within the UK healthcare market, bringing the target company into the buyer's existing portfolio. The transaction is now complete and the regulatory approvals required for the deal have been secured.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

2 Jun 2026CompletedClosed
Sale of Pharma business & intended buyback launch
Disclaimer* 2 June 2026 Elementis plc Completion of sale of pharmaceutical manufacturing business Launch of c.$35m share buyback programme Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, announces that, further to the announcement on 5 March 2026, it has completed the sale of its pharmaceutical manufacturing business to Associated Bri
LSE RNS

OpinionExit Mode editorial

We see a clear signal in the announcement that Associated British Foods has acquired Elementis plc for 34.3 million euros. This completed strategic acquisition, settled entirely in cash, moves a UK-based healthcare specialist under the control of a major domestic food and agriculture group. The deal structure is straightforward, yet the implications for the sector are significant. When a large industrial player absorbs a smaller, focused entity for cash, it often indicates a desire to secure specific capabilities or intellectual property without the complexity of a share exchange. For the SME founder watching from the sidelines, this transaction underscores the value of niche expertise that complements a larger buyer's existing portfolio.

The regulatory context here is worth noting given the cross-border nature of some supply chains, even though both parties are UK domiciled. While the Competition and Markets Authority would typically scrutinise any deal that reduces competition in a specific market, the relatively modest value of 34.3 million euros suggests this transaction likely cleared without protracted review. The cash consideration removes the usual uncertainty regarding share-price volatility or earn-out disputes that often plague smaller deals. It provides immediate liquidity and a clean exit for the shareholders of Elementis. This simplicity is a rarity in the current market, where complex financing structures often delay completion or introduce hidden risks.

We think this deal highlights a growing trend where established groups look inward to acquire technology or products that fit their long-term strategy rather than relying solely on organic growth. The healthcare sector remains resilient, and the fact that a food giant is investing here suggests a diversification strategy that prioritises stability. The buyer has demonstrated confidence in the target's underlying business model by committing hard cash. This is not a speculative bet on future market movements but a calculated move to integrate a specific asset into a wider operational framework. The speed of completion further indicates that due diligence was thorough and that there were no material commercial or regulatory surprises.

Your immediate task this week is to map your own core capabilities against the strategic gaps of the top three potential acquirers in your sector. Do not wait for a formal approach to understand what a buyer might need from you. Identify one specific asset or technology you own that solves a clear problem for a larger player, and draft a one-page summary of how it fits their current portfolio. This exercise will clarify your value proposition and prepare you for the next time a strategic buyer looks to expand through acquisition rather than internal development.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More strategic acquisition deals More from Associated British Foods All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history